TNFRSF10A and cancer: Since TRAIL selectively induces apoptosis in cancer cells while sparing normal cells, various formulations of recombinant TRAIL protein and DR4/DR5 binding agonistic antibodies have been evaluated in preclinical models and clinical trials [25,26].